Abstract
Chimeric antigen receptor T-cell (CAR-T) therapies targeting the B-cell maturation antigen are a new class of therapy for treating Relapsed or Refractory Multiple Myeloma (RRMM). As CAR-T therapies are introduced, payers will need to balance the higher efficacy, upfront costs, and total treatment costs when evaluating potential value. We developed a cost per responder (CPR) model which incorporates efficacy and total treatment cost to evaluate the value of RRMM CAR-T therapies (ciltacabtagene autoleucel [cilta-cel] and idecabtagene vicleucel [ide-cel]).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
